To appreciate why this development matters, it helps to understand the logic of targeted protein degradation. Small-molecule inhibitors block the activity of a protein, but degraders eliminate the protein itself, which can be far more effective when the target protein has scaffolding roles, non-enzymatic functions, or the ability to rebound after inhibition. Intracellular protein degradation has been revolutionized by proteolysis-targeting chimeras, or PROTACs, which hijack the ubiquitin-proteasome system to tag unwanted intracellular proteins for destruction. But an estimated 40 percent of the proteome, including most receptors, ligands, and secreted factors implicated in cancer, inflammation, and fibrosis, resides outside the cell or on its surface, beyond the reach of the proteasome. For these targets, the lysosome is the natural destination, and a family of technologies collectively known as lysosome-targeting chimeras, or LYTACs, was conceived to exploit it.

The original LYTAC concept is elegant in principle. A bifunctional molecule carries one binding arm directed at a protein of interest and another directed at a cell-surface receptor that constitutively traffics to the lysosome, such as the cation-independent mannose-6-phosphate receptor or the asialoglycoprotein receptor. By physically linking the target protein to such a receptor, the chimera tricks the cell’s endocytic machinery into internalizing the target along with the receptor. Once in the acidic environment of the lysosome, both the target protein and the chimera are degraded. This mechanism, however, carries two fundamental weaknesses that have limited the technology’s reach. First, degradation is absolutely dependent on the expression level of the shuttling receptor, which varies enormously between cell types, tissues, and disease states, and can itself be saturated or downregulated. Second, because the receptor and the chimera are destroyed along with the cargo, each round of degradation consumes degrading machinery and drug molecules alike, imposing a stoichiometric burden that demands high and repeated dosing and risks depletion of the very receptors the cell needs for its own housekeeping.

The new study set out to solve both problems simultaneously by asking a deceptively simple question: could a degrader exploit the cell’s own bulk transport pathways instead of a dedicated receptor, and could it survive the journey it asks the cell to make? The answer came in the form of a chimera built from a polyzwitterion, a synthetic polymer bearing a balanced arrangement of positive and negative charges, conjugated to a ligand that binds the protein of interest. Polyzwitterions occupy an unusual position in polymer science: their net-neutral charge surfaces resist nonspecific protein adsorption, yet certain architectures interact productively with the plasma membrane in ways that can induce membrane ruffling. The researchers harnessed this property deliberately, showing that their polyzwitterion-ligand conjugates trigger macropinocytosis, a form of endocytosis in which the cell engulfs large gulps of extracellular fluid and whatever solutes it contains, forming large vesicles called macropinosomes. Crucially, macropinocytosis is a receptor-independent process. The cell does not need to recognize a specific receptor-ligand pair; it simply drinks in the surrounding medium, and the chimera rides along with its bound target protein.

Once inside the cell, the chemistry of the endocytic pathway takes over. As endosomes acidify, dropping to a pH of around 5 to 6 in late endosomes and below 5 in lysosomes, the bond between the polyzwitterion carrier and the ligand for the protein of interest cleaves. This pH-responsive dissociation is the linchpin of the design. The target protein, released within the endolysosomal system, proceeds to the lysosome and is degraded by the acidic hydrolases waiting there. The chimera itself, however, is not condemned to the same fate. The researchers demonstrated that the liberated polyzwitterion is routed through the endoplasmic reticulum-Golgi transcytosis pathway, a cellular recycling route normally used to shuttle cargo across the cell from one membrane domain to another. Through this pathway, the intact chimera is exocytosed back into the extracellular space, ready to bind another molecule of its target protein and initiate another round of capture, internalization, release, and degradation. In effect, each McR-TAC molecule operates as a catalytic degrader, turning over many copies of its target rather than being consumed stoichiometrically with each one.

The functional consequences of this design were validated in biologically demanding settings. The team targeted programmed cell death ligand 1, better known as PD-L1, the transmembrane protein through which many tumors suppress antitumor T-cell immunity and which is a cornerstone target of the checkpoint inhibitor class of cancer immunotherapies. They also targeted macrophage migration inhibitory factor, or MIF, a secreted pro-inflammatory cytokine that promotes tumor progression, immune evasion, and metastasis. Both targets were chosen in part because they represent the two categories of proteins that LYTACs are meant to address: a cell-surface membrane protein and a soluble extracellular protein. In a triple-negative breast cancer mouse model, one of the most aggressive and difficult-to-treat breast cancer subtypes, McR-TACs directed against PD-L1 and MIF achieved durable depletion of both proteins from tumor tissue. The degradation was sustained rather than transient, a direct benefit of the recycling mechanism, and the effect translated into a significant inhibition of tumor growth in the treated animals.

The implications of receptor-independent, recyclable degradation extend well beyond these two targets. Receptor-dependent LYTACs are inherently tissue-restricted by receptor expression, which can be an advantage for targeted therapy but a severe limitation when the target cell does not express sufficient receptor or when the receptor is saturated by endogenous ligands. By invoking macropinocytosis, a process that many cells can perform, and whose activity is in fact frequently upregulated in cancer cells as part of their nutrient-scavenging metabolism, McR-TACs sidestep this dependency altogether. This may prove especially valuable in oncology, where the very cells a degrader must enter are often the most macropinocytically active cells in the body. The stoichiometric advantage is equally consequential. A degrader that recycles can achieve the same degree of target knockdown at lower administered doses and with longer effective duration of action, reducing manufacturing burden, cost, and the frequency of administration, all of which are decisive factors in whether a biological drug can reach the clinic.

The study also contributes a conceptual lesson that resonates beyond the specific chemistry involved: the cell’s natural transport pathways constitute a rich, largely untapped pharmacological toolbox. Rather than forcing cells to use artificial routes, McR-TACs recruit physiological processes, macropinocytosis for entry, endosomal acidification for release, and ER-Golgi transcytosis for exit, in a sequence that mirrors how the cell already moves material through its compartments. The authors suggest that this strategy of leveraging natural transport pathways for recyclable protein degradation could be adapted broadly, with different target-binding ligands grafted onto the recyclable polyzwitterion platform to address a wide range of membrane and extracellular proteins implicated in human disease.

Significant work remains before such molecules could approach human trials. The pharmacokinetics, immunogenicity, biodistribution, and long-term safety of polyzwitterion carriers must be characterized, and the efficiency of macropinocytosis induction will need to be validated across a broader spectrum of tissues and cell types. Dosing, formulation, and potential off-target degradation of bystander proteins drawn into macropinosomes all require careful scrutiny. Nevertheless, the demonstration that a single bifunctional molecule can repeatedly shepherd proteins to their destruction while returning intact for another cycle marks a conceptual milestone. If the recyclable paradigm generalizes, it could reshape the design logic of extracellular protein therapeutics much as catalytic turnover reshaped small-molecule drug discovery, turning what was once a stoichiometric war of attrition against disease proteins into a genuinely catalytic one.

The experimental agent, called Pro-LYTAC, belongs to a class of compounds known as lysosome-targeting chimeras, or LYTACs. These molecules are designed to eliminate selected proteins from the surface of cells rather than merely block their activity. A LYTAC typically combines a targeting component that recognizes a cell-surface protein with a ligand capable of engaging the cell’s lysosomal trafficking machinery. Once the complex is internalized, the lysosome—an organelle filled with enzymes that digest proteins and other cellular material—breaks down the targeted protein. This approach is potentially powerful because it can remove disease-promoting proteins that are difficult to inhibit with conventional small-molecule drugs.

The researchers led by Peng Shi and Mohan Chen sought to make this protein-degradation technology more selective by placing it behind a molecular gate. Their Pro-LYTAC is activated by glutathione, a small antioxidant peptide present in cells throughout the body but found at elevated concentrations in many tumors. Glutathione helps maintain the reducing environment inside cells and participates in the detoxification of reactive chemical compounds. By incorporating a glutathione-responsive chemical “cage” into the therapeutic design, the team aimed to prevent the active LYTAC structure from functioning until it encountered the biochemical conditions associated with malignant tissue. In principle, the inactive form can circulate without efficiently binding its target or engaging lysosomal uptake pathways, while the tumor-associated glutathione environment removes the protective lock.

This design transforms a feature of tumor biology into a molecular switch. Cancer cells frequently exhibit altered redox metabolism, increased antioxidant capacity and distinctive concentrations of intracellular metabolites. These differences are not universal across every tumor type, but they can provide chemical signals that are less pronounced in healthy tissues. In the Pro-LYTAC strategy, glutathione serves as the trigger that converts a relatively inert conjugate into a protein-degrading agent. The researchers constructed the therapeutic as a caged glycan-antibody conjugate, linking an antibody-based recognition element with a glycan component that can direct the complex toward lysosomal clearance. The cage is intended to reduce activity before activation, thereby limiting exposure of healthy organs to the fully functional degrader.

After the molecular lock is removed, Pro-LYTAC targets a protein that cancer cells use to avoid immune recognition. Many tumors survive in the body not only because they divide uncontrollably but also because they actively suppress or evade immune attack. Surface proteins involved in immune checkpoint signaling can function as protective shields, transmitting signals that prevent immune cells from efficiently identifying malignant cells as dangerous. By directing one of these immune-evasion proteins to the lysosome, Pro-LYTAC causes its physical removal from the cancer-cell surface. The result is not simply temporary inhibition of a protein’s activity; it is degradation of the protein itself, potentially producing a more sustained change in the cell’s interaction with the immune system.

The researchers evaluated the therapeutic in mouse models of triple-negative breast cancer, an aggressive disease subtype that lacks three commonly exploited molecular targets and therefore remains difficult to treat. During the two-week study, animals receiving Pro-LYTAC showed stronger tumor suppression than control animals treated with saline. The findings indicate that the compound was able to reach tumors, become activated under tumor-associated conditions and engage the intended protein-degradation pathway. Removing the immune-evasion shield is expected to make tumor cells more visible to immune defenses, allowing immune cells to recognize and attack them more effectively. The observed tumor reduction therefore reflects both the direct molecular action of the degrader and the possibility of a secondary antitumor immune response.

The distribution of the compound in the animals provided another important result. Pro-LYTAC was concentrated in tumor tissue, while only small quantities were detected in the liver. The liver is a major site of drug metabolism and clearance, and many therapeutic molecules accumulate there even when the liver is not the intended target. Excessive hepatic exposure can contribute to toxicity and may restrict the dose that can safely be administered. The researchers propose that the locked state of Pro-LYTAC outside the tumor reduces its interactions with healthy tissues and limits the formation of active species in the liver. This could lower the risk of adverse exposure, although detailed toxicology, long-term safety testing and studies in additional animal models will be required before any conclusions about clinical safety can be drawn.

The work also highlights a broader challenge in targeted protein degradation: reaching the right cells is only part of the problem. A degrader may be highly selective for a protein yet still cause toxicity if it remains active while circulating through the body. Conditional activation offers a second layer of control, combining molecular recognition with a biochemical trigger. In the case of Pro-LYTAC, the antibody and glycan components provide the framework for recognition and lysosomal delivery, while the glutathione-sensitive cage is intended to control when that framework becomes operational. Such “prodrug” architectures could eventually be adapted to other tumor-associated signals, including unusual enzyme activity, acidity, oxygen levels or reactive metabolites.

The findings remain an early demonstration in mice rather than evidence of a ready-to-use cancer medicine. Tumors in human patients are chemically and genetically diverse, and glutathione concentrations may vary between tumor types, treatment histories and individual patients. Researchers will need to determine how reliably the cage is removed in human tumors, whether enough active compound reaches malignant cells, how long the degraded protein remains suppressed and whether the immune response can be sustained. They must also assess the possibility of premature activation, immune reactions against the antibody or glycan components, and toxicity caused by unintended protein degradation. Nevertheless, the study presents a compelling route toward safer LYTAC therapy by using the tumor’s own biochemical environment to control drug activity. If the approach can be translated beyond animal models, it may help transform targeted protein degradation from a powerful but potentially broad-acting technology into a more precise weapon against cancer.

Subject of Research: Tumor-selective protein degradation therapy using glutathione-activated Pro-LYTAC for triple-negative breast cancer.

Article Title: “Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras”

Web References: https://doi.org/10.1021/acs.jmedchem.6c01778

References: Journal of Medicinal Chemistry, DOI: 10.1021/acs.jmedchem.6c01778

Keywords

Pro-LYTAC, lysosome-targeting chimera, targeted protein degradation, cancer therapy, triple-negative breast cancer, glutathione, tumor microenvironment, immune evasion, glycan-antibody conjugate, tumor-selective treatment